Becker's Healthcare September 27, 2024
Hundreds of clinical trials are researching how drugs like Ozempic and Mounjaro affect a plethora of conditions, Nature reported Sept. 25.
GLP-1 medications are currently approved for Type 2 diabetes, chronic weight management and/or cardiovascular disease.
Drug manufacturers and researchers are also testing whether these drugs could treat anxiety, depression, suicidal ideation, Alzheimer’s disease, dementia, Parkinson’s disease, arthritis, kidney disease, cancer, metabolic dysfunction-associated steatohepatitis, alcohol and drug addiction, polycystic ovary syndrome, infertility and sleep apnea.
A few late-stage trials have found promising results for some of these conditions.
In April, Eli Lilly announced plans to request FDA approval for Zepbound, a weight loss drug, as a treatment for sleep apnea. In June, Novo Nordisk said the FDA...
Today's Sponsors
Today's Sponsor